Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation. (2016)

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1158/1535-7163.mct-15-0815

PubMed Identifier: 27048952

Publication URI: http://europepmc.org/abstract/MED/27048952

Type: Journal Article/Review

Volume: 15

Parent Publication: Molecular cancer therapeutics

Issue: 6

ISSN: 1535-7163